IP Library Granted Patent US 10,712,353
Granted Patent B2
US 10,712,353 · App. 15/590,936 · Granted Jul 14, 2020

Antibodies to olanzapine haptens and use thereof

Inventors: Eric Hryhorenko (Hilton, NY); Banumathi Sankaran (Lexington, MA); Thomas R. DeCory (Pittsford, NY); Theresa Tubbs (Rochester, NY); Linda Colt (Rochester, NY); Bart M. Remmerie (Ghent, BE); Rhys Salter (Doylestown, PA); Matthew Garrett Donahue (Hattiesburg, MS); Yong Gong (Warrington, PA)
Assignee: Janssen Pharmaceutica NV
G01N33/948C07K16/44C12N5/163C12N15/02G01N33/94G01N2800/302
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,712,353
App. No.
15/590,936
Granted
Jul 14, 2020
Kind
B2
Abstract

Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

Claims (14)

1. A method of producing an antibody which binds to olanzapine, the method comprising:

selecting a host for antibody production; and

(ii) inoculating the host with a conjugate having the formula:

wherein the host produces the antibody which binds to olanzapine.

2. A method of producing a hybridoma cell line capable of producing a monoclonal antibody which binds to olanzapine, the method comprising:

(i) selecting a host for antibody production;

(ii) inoculating the host with a conjugate having the formula:

(iii) fusing a cell line from said inoculated host with a continuously dividing cell to create a fused cell capable of producing the monoclonal antibody which binds to olanzapine; and

(iv) cloning the fused cell so as to obtain a hybridoma cell line.

3. The method of claim 1 , wherein the protein is keyhole limpet hemocyanin, bovine thyroglobulin, or ovalbumin.

4. The method of claim 2 , wherein the protein is keyhole limpet hemocyanin, bovine thyroglobulin, or ovalbumin.

5. The method of claim 1 , further comprising generating an antibody binding fragment from the antibody which binds to olanzapine, wherein the antibody binding fragment is selected from the group of fragments consisting of Fv, F(ab′), F(ab′)2, scFv, minibody and diabody fragments.

6. The method of claim 1 , wherein the antibody specifically binds to olanzapine, wherein a dissociation constant of the antibody and olanzapine is less than or equal to 1 μM.

7. The method of claim 2 , wherein the hybridoma cell line is capable of producing a monoclonal antibody which specifically binds to olanzapine, wherein a dissociation constant of the monoclonal antibody and olanzapine is less than or equal to 1 μM.

Continuity (3)
Division 13971519 · Aug 20, 2013
Provisional Application 61691572 · Aug 21, 2012
Related Publication 20170240653A1 · Aug 24, 2017